Top

Published in:

01-01-2015 | Epidemiology

Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and risk of breast cancer

Authors: Kimberly A. Bertrand, Bernard Rosner, A. Heather Eliassen, Susan E. Hankinson, Kathryn M. Rexrode, Walter Willett, Rulla M. Tamimi

Published in: Breast Cancer Research and Treatment | Issue 2/2015

Abstract

Epidemiologic evidence for an association between plasma 25-hydroxyvitamin D [25(OH)D] and breast cancer is inconsistent. Data are especially limited for premenopausal women and for associations with mammographic density. To test the hypothesis that plasma concentration of 25(OH)D is associated with mammographic density, we conducted a cross-sectional study among 835 premenopausal women in the Nurses’ Health Studies. We measured 25(OH)D in blood samples and used multivariable linear regression to quantify the association of average percent density by quartile of plasma 25(OH)D. In a nested case-control analysis including 493 breast cancer cases, we evaluated risk of breast cancer associated with vitamin D status within tertiles of mammographic density. Women in the top quartile of plasma 25(OH)D levels had an average percent breast density 5.2 percentage points higher than women in the bottom quartile (95 % confidence interval: 1.8, 8.7; P trend <0.01), after adjusting for predictors of 25(OH)D and established breast cancer risk factors. Plasma 25(OH)D concentration was significantly inversely associated with breast cancer risk among women with high mammographic density (P trend < 0.01) but not among women in lower tertiles of mammographic density (P-interaction < 0.01). These results do not support the hypothesis that vitamin D is inversely associated with percent mammographic density in premenopausal women. There was evidence that the association between premenopausal 25(OH)D and breast cancer risk varies by mammographic density, with an inverse association apparent only among women with high mammographic density.

Available only for authorised users

Bertone-Johnson ER, Chen WY, Holick MF, Hollis BW, Colditz GA, Willett WC, Hankinson SE (2005) Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomark Prev 14(8):1991–1997CrossRef

Freedman DM, Chang SC, Falk RT, Purdue MP, Huang WY, McCarty CA, Hollis BW, Graubard BI, Berg CD, Ziegler RG (2008) Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomark Prev 17(4):889–894CrossRef

Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O’Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100(22):1581–1591PubMedCentralPubMedCrossRef

Rejnmark L, Tietze A, Vestergaard P, Buhl L, Lehbrink M, Heickendorff L, Mosekilde L (2009) Reduced prediagnostic 25-hydroxyvitamin D levels in women with breast cancer: a nested case-control study. Cancer Epidemiol Biomark Prev 18(10):2655–2660CrossRef

McCullough ML, Stevens VL, Patel R, Jacobs EJ, Bain EB, Horst RL, Gapstur SM, Thun MJ, Calle EE (2009) Serum 25-hydroxyvitamin D concentrations and postmenopausal breast cancer risk: a nested case control study in the Cancer Prevention Study-II Nutrition Cohort. Breast Cancer Res 11(4):R64PubMedCentralPubMedCrossRef

Agborsangaya CB, Surcel HM, Toriola AT, Pukkala E, Parkkila S, Tuohimaa P, Lukanova A, Lehtinen M (2010) Serum 25-hydroxyvitamin D at pregnancy and risk of breast cancer in a prospective study. Eur J Cancer 46(3):467–470PubMedCrossRef

Almquist M, Bondeson AG, Bondeson L, Malm J, Manjer J (2010) Serum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study. Int J Cancer 127(9):2159–2168PubMedCrossRef

Engel P, Fagherazzi G, Boutten A, Dupre T, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F (2010) Serum 25(OH) vitamin D and risk of breast cancer: a nested case-control study from the French E3N cohort. Cancer Epidemiol Biomark Prev 19(9):2341–2350CrossRef

Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE (2011) Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res 13(3):R50PubMedCentralPubMedCrossRef

10.

Bauer SR, Hankinson SE, Bertone-Johnson ER, Ding EL (2013) Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Med 92(3):123–131CrossRef

11.

Bilinski K, Boyages J (2013) Association between 25-hydroxyvitamin D concentration and breast cancer risk in an Australian population: an observational case-control study. Breast Cancer Res Treat 137(2):599–607PubMedCrossRef

12.

Chen P, Li M, Gu X, Liu Y, Li X, Li C, Wang Y, Xie D, Wang F, Yu C, Li J, Chen X, Chu R, Zhu J, Ou Z, Wang H (2013) Higher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies. PLoS One 8(1):e49312PubMedCentralPubMedCrossRef

13.

Kuhn T, Kaaks R, Becker S, Eomois PP, Clavel-Chapelon F, Kvaskoff M, Dossus L, Tjonneland A, Olsen A, Overvad K, Chang-Claude J, Lukanova A, Buijsse B, Boeing H, Trichopoulou A, Lagiou P, Bamia C, Masala G, Krogh V, Sacerdote C, Tumino R, Mattiello A, Buckland G, Sanchez MJ, Menendez V, Chirlaque MD, Barricarte A, Bueno-de-Mesquita HB, van Duijnhoven FJ, van Gils CH, Bakker MF, Weiderpass E, Skeie G, Brustad M, Andersson A, Sund M, Wareham N, Khaw KT, Travis RC, Schmidt JA, Rinaldi S, Romieu I, Gallo V, Murphy N, Riboli E, Linseisen J (2013) Plasma 25-hydroxyvitamin D and the risk of breast cancer in the European prospective investigation into cancer and nutrition: a nested case-control study. Int J Cancer 133(7):1689–1700PubMedCrossRef

14.

Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H (2010) Meta-analysis: serum vitamin D and breast cancer risk. Eur J Cancer 46(12):2196–2205PubMedCrossRef

15.

Wang D, de-la Paz OIV, Zhai JX, Liu DW (2013) Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. Tumour Biol 34(6):3509–3517PubMedCrossRef

16.

Wang J, Eliassen AH, Spiegelman D, Willett WC, Hankinson SE (2014) Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses’ Health Study II. Cancer Causes Control 25(7):819–827PubMedCentralPubMedCrossRef

17.

McCormack VA, dos Santos Silva I (2006) Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev 15(6):1159–1169CrossRef

18.

Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S (2010) Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst 102(16):1224–1237PubMedCentralPubMedCrossRef

19.

Welsh J (2011) Vitamin D metabolism in mammary gland and breast cancer. Mol Cell Endocrinol 347(1–2):55–60PubMedCrossRef

20.

Heo DS, Lee JG, Hwang HR, Lee SY, Cho BM, Kim SS, Jeong DW, Yi YH, Cho YH, Kim YJ (2014) The association between 25-hydroxyvitamin D and mammographic density in healthy pre- and postmenopausal women regardless of the menstrual cycle phase: a cross-sectional study. Nutr Cancer 66(1):97–103PubMedCrossRef

21.

Crew KD, Campbell J, Reynolds D, Fulton L, Flom JD, Liao Y, Tehranifar P, Terry MB (2014) Mammographic density and serum 25-hydroxyvitamin D levels. Nutr Metab 11(1):18CrossRef

22.

Sprague BL, Trentham-Dietz A, Gangnon RE, Buist DS, Burnside ES, Aiello Bowles EJ, Stanczyk FZ, Sisney GS, Skinner HG (2012) The vitamin D pathway and mammographic breast density among postmenopausal women. Breast Cancer Res Treat 131(1):255–265PubMedCentralPubMedCrossRef

23.

Green AK, Hankinson SE, Bertone-Johnson ER, Tamimi RM (2010) Mammographic density, plasma vitamin D levels and risk of breast cancer in postmenopausal women. Int J Cancer 127(3):667–674PubMedCentralPubMedCrossRef

24.

Chai W, Maskarinec G, Cooney RV (2010) Serum 25-hydroxyvitamin D levels and mammographic density among premenopausal women in a multiethnic population. Eur J Clin Nutr 64(6):652–654PubMedCentralPubMedCrossRef

25.

Knight JA, Vachon CM, Vierkant RA, Vieth R, Cerhan JR, Sellers TA (2006) No association between 25-hydroxyvitamin D and mammographic density. Cancer Epidemiol Biomark Prev 15(10):1988–1992. doi:10.1158/1055-9965.epi-06-0241 CrossRef

26.

Neuhouser ML, Bernstein L, Hollis BW, Xiao L, Ambs A, Baumgartner K, Baumgartner R, McTiernan A, Ballard-Barbash R (2010) Serum vitamin D and breast density in breast cancer survivors. Cancer Epidemiol Biomark Prev 19(2):412–417CrossRef

27.

Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B (2007) Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin D. Cancer Epidemiol Biomark Prev 16(5):929–933CrossRef

28.

Yaghjyan L, Colditz GA, Drake B (2012) Vitamin D and mammographic breast density: a systematic review. Cancer Causes Control 23(1):1–13PubMedCentralPubMedCrossRef

29.

Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C, Speizer FE (1995) Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst 87(17):1297–1302PubMedCrossRef

30.

Tworoger SS, Sluss P, Hankinson SE (2006) Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res 66(4):2476–2482PubMedCrossRef

31.

Tamimi RM, Hankinson SE, Colditz GA, Byrne C (2005) Endogenous sex hormone levels and mammographic density among postmenopausal women. Cancer Epidemiol Biomark Prev 14(11 Pt 1):2641–2647CrossRef

32.

Colditz GA, Hankinson SE (2005) The Nurses’ Health Study: lifestyle and health among women. Nat Rev Cancer 5(5):388–396PubMedCrossRef

33.

Bertrand KA, Eliassen AH, Hankinson SE, Gierach GL, Xu X, Rosner B, Ziegler RG, Tamimi RM (2012) Urinary estrogens and estrogen metabolites and mammographic density in premenopausal women. Breast Cancer Res Treat 136(1):277–287. doi:10.1007/s10549-012-2240-0 PubMedCentralPubMedCrossRef

34.

Byng JW, Boyd NF, Little L, Lockwood G, Fishell E, Jong RA, Yaffe MJ (1996) Symmetry of projection in the quantitative analysis of mammographic images. Eur J Cancer Prev 5(5):319–327PubMedCrossRef

35.

Pettersson A, Hankinson SE, Willett WC, Lagiou P, Trichopoulos D, Tamimi RM (2011) Nondense mammographic area and risk of breast cancer. Breast Cancer Res 13(5):R100PubMedCentralPubMedCrossRef

36.

Rosner B, Cook N, Portman R, Daniels S, Falkner B (2008) Determination of blood pressure percentiles in normal-weight children: some methodological issues. Am J Epidemiol 167(6):653–666PubMedCrossRef

37.

Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE (2000) Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 60(14):3744–3748PubMed

38.

Stone J, Ding J, Warren RM, Duffy SW, Hopper JL (2010) Using mammographic density to predict breast cancer risk: dense area or percentage dense area. Breast Cancer Res 12(6):R97PubMedCentralPubMedCrossRef

39.

Lokate M, Peeters PH, Peelen LM, Haars G, Veldhuis WB, van Gils CH (2011) Mammographic density and breast cancer risk: the role of the fat surrounding the fibroglandular tissue. Breast Cancer Res 13(5):R103PubMedCentralPubMedCrossRef

40.

Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L, Vachon C, Bakker MF, Giles GG, Chia KS, Czene K, Eriksson L, Hall P, Hartman M, Warren RM, Hislop G, Chiarelli AM, Hopper JL, Krishnan K, Li J, Li Q, Pagano I, Rosner BA, Wong CS, Scott C, Stone J, Maskarinec G, Boyd NF, van Gils CH, Tamimi RM (2014) Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst 106(5):dju08CrossRef

41.

Chen TC, Turner AK, Holick MF (1990) Methods for the determination of the circulating concentration of 25-hydroxyvitamin D. J Nutr Biochem 1(6):315–319PubMedCrossRef

42.

Hollis BW (1997) Quantitation of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D by radioimmunoassay using radioiodinated tracers. Methods Enzymol 282:174–186PubMedCrossRef

43.

Rice MS, Tworoger SS, Rosner BA, Pollak MN, Hankinson SE, Tamimi RM (2012) Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, growth hormone, and mammographic density in the Nurses’ Health Studies. Breast Cancer Res Treat 136(3):805–812PubMedCentralPubMedCrossRef

44.

Vachon CM, Kuni CC, Anderson K, Anderson VE, Sellers TA (2000) Association of mammographically defined percent breast density with epidemiologic risk factors for breast cancer (United States). Cancer Causes Control 11(7):653–662PubMedCrossRef

45.

Boyd NF, Lockwood GA, Byng JW, Little LE, Yaffe MJ, Tritchler DL (1998) The relationship of anthropometric measures to radiological features of the breast in premenopausal women. Br J Cancer 78(9):1233–1238PubMedCentralPubMedCrossRef

46.

Samimi G, Colditz GA, Baer HJ, Tamimi RM (2008) Measures of energy balance and mammographic density in the Nurses’ Health Study. Breast Cancer Res Treat 109(1):113–122PubMedCrossRef

47.

McCullough ML, Weinstein SJ, Freedman DM, Helzlsouer K, Flanders WD, Koenig K, Kolonel L, Laden F, Le Marchand L, Purdue M, Snyder K, Stevens VL, Stolzenberg-Solomon R, Virtamo J, Yang G, Yu K, Zheng W, Albanes D, Ashby J, Bertrand K, Cai H, Chen Y, Gallicchio L, Giovannucci E, Jacobs EJ, Hankinson SE, Hartge P, Hartmuller V, Harvey C, Hayes RB, Horst RL, Shu XO (2010) Correlates of circulating 25-hydroxyvitamin D: cohort consortium vitamin D pooling project of rarer cancers. Am J Epidemiol 172(1):21–35PubMedCentralPubMedCrossRef

48.

Kotsopoulos J, Tworoger SS, Campos H, Chung FL, Clevenger CV, Franke AA, Mantzoros CS, Ricchiuti V, Willett WC, Hankinson SE, Eliassen AH (2010) Reproducibility of plasma and urine biomarkers among premenopausal and postmenopausal women from the Nurses’ Health Studies. Cancer Epidemiol Biomark Prev 19(4):938–946CrossRef

Title: Premenopausal plasma 25-hydroxyvitamin D, mammographic density, and risk of breast cancer
Authors: Kimberly A. Bertrand
Bernard Rosner
A. Heather Eliassen
Susan E. Hankinson
Kathryn M. Rexrode
Walter Willett
Rulla M. Tamimi
Publication date: 01-01-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 2/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-014-3247-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2

The prognostic relevance of the mitotic activity index in axillary lymph node-negative breast cancer

Invasive lobular carcinoma of the breast: local recurrence after breast-conserving therapy by subtype approximation and surgical margin

Long-term clinical outcomes in women with breast pain in the absence of additional clinical findings: mammography remains indicated

Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial

Keynote webinar | Spotlight on antibody–drug conjugates in cancer